JP2016525546A5 - - Google Patents

Download PDF

Info

Publication number
JP2016525546A5
JP2016525546A5 JP2016529856A JP2016529856A JP2016525546A5 JP 2016525546 A5 JP2016525546 A5 JP 2016525546A5 JP 2016529856 A JP2016529856 A JP 2016529856A JP 2016529856 A JP2016529856 A JP 2016529856A JP 2016525546 A5 JP2016525546 A5 JP 2016525546A5
Authority
JP
Japan
Prior art keywords
compound
formula
subject
administered
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016529856A
Other languages
English (en)
Japanese (ja)
Other versions
JP6363192B2 (ja
JP2016525546A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/047797 external-priority patent/WO2015013395A1/en
Publication of JP2016525546A publication Critical patent/JP2016525546A/ja
Publication of JP2016525546A5 publication Critical patent/JP2016525546A5/ja
Application granted granted Critical
Publication of JP6363192B2 publication Critical patent/JP6363192B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016529856A 2013-07-25 2014-07-23 トリグリセリド、総コレステロール、及び低密度リポタンパク質の血中濃度を低減する方法 Active JP6363192B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361858450P 2013-07-25 2013-07-25
US61/858,450 2013-07-25
PCT/US2014/047797 WO2015013395A1 (en) 2013-07-25 2014-07-23 Methods for reducing triglyceride, total cholesterol and low density lipoprotein blood levels

Publications (3)

Publication Number Publication Date
JP2016525546A JP2016525546A (ja) 2016-08-25
JP2016525546A5 true JP2016525546A5 (enExample) 2017-09-21
JP6363192B2 JP6363192B2 (ja) 2018-07-25

Family

ID=52391020

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016529856A Active JP6363192B2 (ja) 2013-07-25 2014-07-23 トリグリセリド、総コレステロール、及び低密度リポタンパク質の血中濃度を低減する方法

Country Status (9)

Country Link
US (2) US20150031769A1 (enExample)
EP (1) EP3024454B1 (enExample)
JP (1) JP6363192B2 (enExample)
KR (1) KR102352728B1 (enExample)
CN (1) CN105407884B (enExample)
BR (1) BR112016001400B1 (enExample)
CA (1) CA2917780C (enExample)
ES (1) ES2843511T3 (enExample)
WO (1) WO2015013395A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024522030A (ja) 2021-05-28 2024-06-10 メディシノバ・インコーポレイテッド フェノキシアルキルカルボン酸誘導体、およびトリグリセリドレベルを低下させることにおけるその使用
WO2024117173A1 (ja) 2022-11-30 2024-06-06 花王株式会社 痒みの予防又は改善剤

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2585246A1 (fr) 1985-07-26 1987-01-30 Cortial Procede d'obtention de formes pharmaceutiques solides a liberation prolongee
US4788055A (en) 1985-12-09 1988-11-29 Ciba-Geigy Corporation Resinate sustained release dextromethorphan composition
GB8613688D0 (en) 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
GB8613689D0 (en) 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
US4816264A (en) 1986-06-06 1989-03-28 Warner-Lambert Company Sustained release formulations
US4985585A (en) 1988-03-07 1991-01-15 Kyorin Pharmaceutical Co., Ltd. Phenoxyalkylcarboxylic acid derivatives and process for their preparations
US4996047A (en) 1988-11-02 1991-02-26 Richardson-Vicks, Inc. Sustained release drug-resin complexes
CA2002492A1 (en) 1988-11-11 1990-05-11 Sandra T. A. Malkowska Pharmaceutical ion exchange resin composition
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5290812A (en) 1991-01-18 1994-03-01 Kyorin Pharmaceutical Co., Ltd. Phenoxyalkylcarboxylic acid derivatives and process of preparing the same
US7060854B2 (en) 2003-06-24 2006-06-13 Medicinova, Inc. Process for making polymorphic form A of 4-[6-acetyl-3-[3-(4-acetyl-3-hydroxy-2-propylphenylthio)propoxy]-2-propylphenoxy]butyric acid
US7064146B2 (en) 2003-06-24 2006-06-20 Medicinova, Inc. Pharmaceutical compositions of isolated orthorhombic crystalline 4-[6-acetyl-3-[3-(4-acetyl-3-hydroxy-2-propylphenylthio)propoxy]-2-propylphenoxy]butyric acid and methods of use
KR20070058381A (ko) * 2004-04-27 2007-06-08 메디시노바, 인크. 염증성 질환 치료용 페녹시알킬카르복실 산 유도체
AU2005259864A1 (en) * 2004-06-30 2006-01-12 Combinatorx, Incorporated Methods and reagents for the treatment of metabolic disorders
CN101193656B (zh) * 2005-06-08 2011-03-02 兴和株式会社 甘油三酸酯降低剂
WO2009002746A1 (en) * 2007-06-22 2008-12-31 Decode Genetics Ehf. Dosing schedules of leukotriene synthesis inhibitors for human therapy

Similar Documents

Publication Publication Date Title
HRP20211314T1 (hr) 19-nor c3,3-disupstituirani c21-n-pirazolil steroidi i postupci za njihovu uporabu
HRP20181048T1 (hr) Neuroaktivni 19-alkoksi-17-supstituirani steroidi, korisni u postupcima liječenja
ES2752039T3 (es) Agente terapéutico para la dislipidemia
RU2018114447A (ru) Введение дейтерированных усилителей cftr
JP2013522326A5 (enExample)
HK1221646A1 (zh) 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途
JP2014508753A5 (enExample)
RU2013121788A (ru) Ингибиторы репликации вич
JP2013525444A5 (enExample)
JP2014515351A5 (enExample)
EP4327886A3 (en) Pyrimido- pyridazinone compounds and use thereof
EA201390659A1 (ru) Способы лечения с применением липидных соединений
JP2015509075A5 (enExample)
JP2016511753A5 (enExample)
WO2012071369A3 (en) A non-retinoid rbp4 antagonist for treatment of age-related macular degeneration and stargardt disease
RU2013150861A (ru) Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний
EA201270071A1 (ru) Способ лечения пациента, нуждающегося в аспириновой терапии
JP2017519028A5 (enExample)
JP2016513124A5 (enExample)
RU2015102831A (ru) ПРИМЕНЕНИЕ 2-МЕТИЛЕН-19-НОР-(20S)-1α, 25-ДИГИДРОКСИВИТАМИНА D3 ДЛЯ ЛЕЧЕНИЯ ВТОРИЧНОГО ГИПЕРПАРАТИРЕОЗА
JP2017536380A (ja) 15−hepeを含む組成物、およびそれを用いて線維症を処置または防止する方法
RU2015127834A (ru) Способы лечения диабета путем введения антагониста рецептора глюкагона в сочетании с ингибитором поглощения холестерина
JP2016525546A5 (enExample)
EP2753310A4 (de) Formulierung zur kontrollierten freisetzung eines oder mehreren stoffe im verdauungstrakt eines säugetiers
JP2013523758A5 (enExample)